Extrel CMS Announces ATEX Approval for Process Mass Spectrometer

PITTSBURGH, April 13 /PRNewswire/ -- Extrel CMS announces ATEX approval for process mass spectrometer. The MAX300-IGX Industrial Mass Spectrometer is suitable for use in potentially explosive atmospheres.

The Extrel MAX300-IGX Process Mass Spectrometer has obtained ATEX approval for installations in Zone 1 areas. The MAX300-IGX version will meet the ATEX area classification requirements of European Pharmaceutical and Petrochemical producers. The MAX300-IGX is the newest addition to Extrel's process mass spectrometer product line. The MAX300-IG is also available in general purpose, hazardous area and CSA certified versions.

The Extrel MAX300 series Mass Spectrometers are the seventh generation of high performance online quadrupole mass spectrometers. The MAX300 provides real time gas analysis and is suitable for a variety of applications including: pharmaceutical solvent drying, fermentation control, ethylene, ethylene oxide, ambient air monitoring, ammonia process control and various steel processes.

About Extrel CMS:

Extrel CMS is an ISO 9001:2000 quality management system certified manufacturer of mass spectrometers for Process Control, Process Development, Basic Research, and QA/QC Laboratories. Extrel's analyzers and mass spectrometer components are used in a wide range of markets including: Hydrocarbon Processing, Chemicals, Environmental, Pharmaceutical, Semiconductor, Steel, Materials, Energy, Aerospace and Automotive.

For more information contact Extrel CMS, 575 Epsilon Drive, Pittsburgh, PA 15238. Phone: 412-963-7530. Fax: 412-963-6578. Web Site: www.extrel.com

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE Extrel CMS

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.